Fetroja® (cefiderocol) – New indication
September 28, 2020 - Shionogi announced the FDA approval of Fetroja (cefiderocol), in patients 18 years of age or older for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), caused by the following susceptible Gram-negative microorganisms: Acinetobacter baumannii complex, Escherichia coli, Enterobacter cloacae complex, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens.
Top